The complement system: Pathophysiology and clinical relevance

Wiener Klinische Wochenschrift

Volumn 111, Issue 10, 1999, Pages 378-391

  Speth, Cornelia ^a   Würzner, Reinhard ^a   Stoiber, Heribert ^a   Dierich, Manfred P ^a,b,c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Institut für Hygiene und Sozialmedizin   (Austria)

Author keywords

Alzheimer; Complement; Dermatology; Molecular mimicry; Multiple sclerosis; Nephrology; Neurology; Viral infection; Xenotransplantation

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT RECEPTOR; PROPERDIN;

ALZHEIMER DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; COMPLEX FORMATION; HUMAN; KIDNEY DISEASE; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SKIN DISEASE; VIRUS INFECTION; VIRUS NEUTRALIZATION; XENOTRANSPLANTATION;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; KIDNEY DISEASES; NERVOUS SYSTEM DISEASES; SKIN DISEASES; TRANSPLANTATION, HETEROLOGOUS; VIRUS DISEASES;

EID: 0344435247     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Harrison RA, Lachmann PJ (1980) The physiological breakdown of the third component of human complement. Mol Immunol 17: 9-20
2. Klein E, Di Renzo L, Yefenof E (1990) Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol 27: 1343-1347
3. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A (1996) C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 157: 1693-1698
4. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA (1996) A new biological role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 156: 3455-3460
5. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA (1996) Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 20: 1-9
6. Schonermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hansch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136: 1772-1776
7. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ (1990) Human protectin (CD59), an 18000-20000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9
8. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT (1984) Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81: 4510-4514
9. Habicht GS, Beck G, Ghebrehiwet B (1987) C1q inhibits the expression of B lymphoblastoid cell line interleukin 1 (IL-1). J Immunol 138: 2593-2597
10. Kuna P, Iyer M, Peerschke EI, Kaplan AP, Reid KB, Ghebrehiwet B (1996) Human C1q induces eosinophil migration. Clin Immunol Immunopathol 81: 48-54
11. Rother K, Till GO, Hänsch GM (eds) (1998) The complement system, 2nd edn. Springer, Berlin Heidelberg New York Tokyo
12. Jokiranta TS, Jokipii L, Meri S (1995) Complement resistance of parasites. Scand J Immunol 42: 9-20
13. Cooper NR (1998) Complement-dependent virus neutralization. In: Rother K, Till GO, Hänsch GM (eds) The complement system, 2nd edn. Springer, Berlin Heidelberg New York Tokyo, pp 302-309
14. Oldstone MB, Cooper NR, Larson DL (1974) Formation and biological role of polyoma virus-antibody complexes. J Exp Med 140: 549-565
15. Welsh RM, Lampert PW, Burner PA, Oldstone MBA (1976) Antibody and complement interactions with purified lymphocytic coriomeningitis virus. Virology 73: 59-71
16. Stoiber H, Thielens NM, Ebenbichler C, Arlaud GJ, Dierich MP (1994) The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 24: 294-300
17. Beebe DP, Schreiber RD, Cooper NR (1983) Neutralization of influenza virus by normal human sera; mechanisms involving antibody and complement. J Immunol 130: 1317-1322
18. Leddy JP, Simons RL, Douglas RD (1977) Effect of selective complement deficiency on the rate of of neutralization of enveloped viruses by human sera. J Immunol 118: 28-34
19. Nemerow GR, Jensen FC, Cooper NR (1982) Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest 70: 1081-1091
20. Welsh RM (1977) Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J Immunol 118: 348-354
21. Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF (1991) Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS-Res Hum Retroviruses 7: 579-585
22. Lachmann PJ, Davies A (1997) Complement and immunity to viruses. Immunol Reviews 159: 69-77
23. Bartholomew RM, Esser AF, Muller-Eberhard HJ (1978) Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 147: 844-853
24. Welsh R Jr., Cooper NR, Jensen FC, Oldstone MB (1975) Human serum lyses RNA tumour viruses. Nature 257: 612-614
25. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP (1991) Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174: 1417-1424
26. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MK (1996) Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379: 85-88
27. Takefman DM, Sullivan BL, Sha BE, Spear GT (1998) Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 246: 370-378
28. Speth C, Kacani L, Dierich MP (1997) Complement receptors in HIV infection. Immunol Reviews 157: 49-67
29. Dierich MP, Ebenbichler CF, Marschang P, Fust G, Thielens NM, Arlaud GJ (1993) HIV and human complement: mechanisms of interaction and biological implication. Immunol Today 14: 435-440
30. Stoiber H, Clivio A, Dierich MP (1997) Role of complement in HIV infection. Ann Rev Immunol 15: 649-674
31. Tremblay MJ, Fortin J-F, Cantin R (1998) The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 19: 346-351
32. Frank I, Stoiber H, Godar S, Möst J, Stockinger H, Dierich MP (1996) Aquisition of host cell-surface-derived molecules by HIV-1. AIDS 10: 1611-1620
33. Stoiber H, Pinter C, Siccardi A, Clivio A. Dierich MP (1996) Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183: 307-310
34. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL (1998) Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95: 7544-7549
35. Mold C, Bradt BM, Nemerow GR, Cooper NR (1988) Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med 168: 949-969
36. Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell 50: 819-820
37. Kotwal GJ, Moss B (1988) Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178
38. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM (1992) Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166: 1245-1250
39. Isaacs SN, Kotwal GJ, Moss B (1992) Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 89: 628-632
40. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB (1984) Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309: 633-635
41. Seidel-Dugan C, Ponce de Leon M, Friedman HM, Eisenberg RJ, Cohen GH (1990) Identification of C3b-binding regions on herpes simplex virus type 2 glycoprotein C. J Virol 64: 1897-1906
42. Neipel F, Albrecht JC, Fleckenstein B (1997) Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol 71: 4187-4192
43. Fodor WL, Rollins SA, Bianco-Caron S, Rother RP, Guilmette ER, Burton WV et al (1995) The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J Virol 69: 3889-3892
44. Albrecht JC, Nicholas J, Cameron KR, Newman C, Fleckenstein B, Honess RW (1992) Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology 190: 527-530
45. Solder BM, Reisinger EC, Koefler D, Bitterlich G, Wachter H, Dierich MP (1989) Complement receptors: another port of entry for HIV. Lancet 2: 271-272
46. Reisinger EC, Vogetseder W, Berzow D, Kofler D, Bitterlich G, Lehr HA, Wachter H, Dierich MP (1990) Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS 4: 961-965
47. Delibrias CC, Kazatchkine MD, Fischer E (1993) Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 38: 183-189
48. Legendre C, Gras G, Krzysiek R, Galanaud P, Richard Y, Dormont D (1996) Mechanisms of opsonized HIV entry in normal B lymphocytes. FEBS Lett 381: 227-232
49. Stoiber H, Frank I, Spruth M, Schwendinger M, Müllauer B, Windisch JM, Schneider R, Katinger H, Ando I, Dierich MP (1997) Inhibiton of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol 34:855-863
50. Stoiber H, Ebenbichler C, Schneider R, Janatova J, Dierich MP (1995) Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 9: 19-26
51. Stoiber H, Schneider R, Janatova J, Dierich MP (1995) Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 193: 98-113
52. Halstead SB (1989) Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11: 830-839
53. Johnson DC, Hill AB (1998) Herpesvirus evasion of the immune system. Curr Top Microbiol Immunol 232: 149-177
54. Nemerow GR, Houghten RA, Moore MD, Cooper NR (1989) Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56: 369-377
55. Dorig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305
56. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032
57. Prodinger WM, Würzner R, Erdei A, Dierich MP (1998) Complement. In: Paul WE (ed) Fundamental immunology. Lippincott-Raven, Philadelphia, pp 967-995
58. Würzner R, Werfel T (1997) Das Komplementsystem: Theoretische und praktische Aspekte bei dermatologischen und allergologischen Erkrankungen. Hautarzt 48: 588-596
59. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic antibodies. Nature Genetics 19: 56-59
60. Würzner R, Orren A, Lachmann PJ (1992) Inherited deficiencies of the terminal components of human complement. Immunodef Rev 3: 123-147
61. Yancey KB, Lawley TJ (1998) Role of complement in diseased and normal human skin. In: Volanakis JE, Frank MM (eds) The human complement system in health and disease. Marcel Dekker, New York, pp 597-618
62. West C (1998) Complement and glomerular disease. In: Volanakis JE, Frank MM (eds) The human complement system in health and disease. Marcel Dekker, New York, pp 571-596
63. Mathieson PW, Würzner R, Oliveira DBG, Lachmann PJ, Peters DK (1993) Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 177: 1827-1831
64. Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M (1995) Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95: 1054-1061
65. Meri S, Koisteinen V, Meittinen A, Tornroth T, Seppala IJT (1992) Activation of the alternative pathway of complement by monoclonal γ light chains in membranoproliferative glomerulonephritis. J Exp Med 175: 939-950
66. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994) β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152: 5050-5059
67. Veerhuis R, Janssen I, Hack CE, Eikelenboom P (1996) Early complement components in Alzheimer's disease brains. Acta Neuropathol 91: 53-60
68. Johns TG, Bernard CC (1997) Binding of complement component C1q to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol 34: 33-38
69. van der Laan LJW, Ruuls SR, Weber KS, Lodder IJ, Döpp EA, Dijkstra CD (1996) Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-a and nitric oxide. J Neuroimmunol 70: 145-152
70. Morgan BP (1995) Complement regulatory molecules: application to therapy and transplantation. Immunol Today 16: 257-259
71. Cozzi E, White DJG (1995) The generation of transgenic pigs as potential organ donors for humans. Nature Medicine 1: 964-966
72. Ryan US (1995) Complement inhibitory therapeutics and xenotransplantation. Nature Medicine 1: 967-968
73. Weiss RA (1998) Transgenic pigs and virus adaptation. Nature 391: 327-328